Evaluating Hearing Loss in Patients Undergoing Second Line Anti Tubercular Treatment

Verma, Jagram; Mohammed, Tara

doi:10.1007/s12070-018-1266-y

Cited by 6 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Audiometry through the uHear app was a convenient method for patients to self-evaluate their hearing, with only a minority of participants not understanding the procedure. uHear app results confirm previous known facts regarding second-line treatment ototoxicity [34,35], with 30 out of the 41 (71%) patients who had aminoglycosides in their treatment scheme experiencing high-frequency hearing loss. Whilst international guidelines from 2018 have removed aminoglycosides from the DR-TB treatment schemes and they are being phased out, it is notable that 36% of participants without an injectable drug also experience hearing loss [36] Hearing loss is the third cause of years lived with disability, after back pain and migraine.…”

Section: Itemsupporting

confidence: 84%

Tuberculosis impacts multiple aspects in quality of life in a Romanian cohort of drug‐susceptible and drug resistant patients: A patient‐reported outcome measures study

Margineanu,

Butnaru,

Lam

et al. 2024

Tropical Med Int Health

View full text Add to dashboard Cite

BackgroundTuberculosis (TB), and especially its drug resistant forms, is responsible for not only significant mortality, but also considerable morbidity, still under‐quantified. This study used four Patient‐Reported Outcome Measures (PROMS) to assess the status of persons affected by drug‐susceptible and drug‐resistant TB during their TB treatment or after treatment completion, in Romania, the highest TB burden country in the EU.MethodsPeople affected by TB in two different regions in Romania were included during and after treatment, following a cross‐sectional design. PROMs used were SF‐36, EQ‐5D‐5L, WPAI and the app‐based audiometry screening tool ‘uHear.’ Descriptive statistics and relevant statistical tests were used to compare groups between themselves and with the general Romanian population.ResultsBoth patients with drug‐susceptible and drug‐resistant TB experience, with drug‐resistant patients experiencing statistically significantly more pain and hearing loss. PROMs show some improvement in the after‐treatment group; however, compared with the general Romanian population for which data were available, all groups scored lower on all outcome measures.ConclusionPROMs offer the possibility of obtaining a more comprehensive view of patients' status, by involving them directly in the medical process and could guide a rehabilitation strategy.

show abstract

Section: Itemsupporting

confidence: 84%

Tuberculosis impacts multiple aspects in quality of life in a Romanian cohort of drug‐susceptible and drug resistant patients: A patient‐reported outcome measures study

Margineanu,

Butnaru,

Lam

et al. 2024

Tropical Med Int Health

View full text Add to dashboard Cite

show abstract

“…Proapoptotic proteins such as BAX change their molecular conformations when they encounter apoptosis signals; they then translocate and insert into the outer mitochondrial membrane, eventually leading to increased permeability of the outer mitochondrial membrane, the release of cytochrome c (Cyt C), and the activation of multiple caspases. BCL-2 can prevent this process ( Verma and Syed Mohammed, 2019 ; Tian et al, 2020 ; Zeng et al, 2020 ). Our study found that the mRNA expression of Bcl-2 was upregulated and that that of Bax was downregulated, indicating that GM1 can relieve neomycin-induced HC damage by regulating the mRNA expression of Bax and Bcl-2 .…”

Section: Discussionmentioning

confidence: 99%

The Ganglioside Monosialotetrahexosylganglioside Protects Auditory Hair Cells Against Neomycin-Induced Cytotoxicity Through Mitochondrial Antioxidation: An in vitro Study

Wang

et al. 2021

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Neomycin is a common ototoxic aminoglycoside antibiotic that causes sensory hearing disorders worldwide, and monosialotetrahexosylganglioside (GM1) is reported to have antioxidant effects that protect various cells. However, little is known about the effect of GM1 on neomycin-induced hair cell (HC) ototoxic damage and related mechanism. In this study, cochlear HC-like HEI-OC-1 cells along with whole-organ explant cultures were used to establish an in vitro neomycin-induced HC damage model, and then the apoptosis rate, the balance of oxidative and antioxidant gene expression, reactive oxygen species (ROS) levels and mitochondrial membrane potential (MMP) were measured. GM1 could maintain the balance of oxidative and antioxidant gene expression, inhibit the accumulation of ROS and proapoptotic gene expression, promoted antioxidant gene expression, and reduce apoptosis after neomycin exposure in HEI-OC-1 cells and cultured cochlear HCs. These results suggested that GM1 could reduce ROS aggregation, maintain mitochondrial function, and improve HC viability in the presence of neomycin, possibly through mitochondrial antioxidation. Hence, GM1 may have potential clinical value in protecting against aminoglycoside-induced HC injury.

show abstract

“…A prospective and retrospective study of 60 patients treated for MDR-TB with aminoglycosides or capreomycin at two hospitals in India from 2011 to 2016 found that 20% of capreomycin treated patients demonstrated permanent high frequency sensorineural hearing loss. Ototoxicity was associated with a large cumulative dose and older age ( 12 ). Records of 115 South-African patients with XDR-TB were retrospectively reviewed.…”

Section: Capreomycin Ototoxicitymentioning

confidence: 99%

Ototoxicity of Non-aminoglycoside Antibiotics

2021

View full text Add to dashboard Cite

It is well-known that aminoglycoside antibiotics can cause significant hearing loss and vestibular deficits that have been described in animal studies and in clinical reports. The purpose of this review is to summarize relevant preclinical and clinical publications that discuss the ototoxicity of non-aminoglycoside antibiotics. The major classes of antibiotics other than aminoglycosides that have been associated with hearing loss in animal studies and in patients are discussed in this report. These antibiotics include: capreomycin, a polypeptide antibiotic that has been used to treat patients with drug-resistant tuberculosis, particularly in developing nations; the macrolides, including erythromycin, azithromycin and clarithromycin; and vancomycin. These antibiotics have been associated with ototoxicity, particularly in neonates. It is critical to be aware of the ototoxic potential of these antibiotics since so much attention has been given to the ototoxicity of aminoglycoside antibiotics in the literature.

show abstract

Evaluating Hearing Loss in Patients Undergoing Second Line Anti Tubercular Treatment

Cited by 6 publications

References 6 publications

Tuberculosis impacts multiple aspects in quality of life in a Romanian cohort of drug‐susceptible and drug resistant patients: A patient‐reported outcome measures study

Tuberculosis impacts multiple aspects in quality of life in a Romanian cohort of drug‐susceptible and drug resistant patients: A patient‐reported outcome measures study

The Ganglioside Monosialotetrahexosylganglioside Protects Auditory Hair Cells Against Neomycin-Induced Cytotoxicity Through Mitochondrial Antioxidation: An in vitro Study

Ototoxicity of Non-aminoglycoside Antibiotics

Contact Info

Product

Resources

About